{"id":"escitalopram-and-sertraline","safety":{"commonSideEffects":[{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"10-20%","effect":"Sexual dysfunction"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SSRIs work by inhibiting the serotonin transporter (SERT), preventing the reuptake of serotonin from the synaptic space back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing serotonergic neurotransmission. Both drugs are commonly used to treat depression and anxiety disorders, though they are typically prescribed as monotherapies rather than in combination.","oneSentence":"Both escitalopram and sertraline are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain by blocking its reabsorption at the synaptic cleft.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:41.430Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Obsessive-compulsive disorder"},{"name":"Post-traumatic stress disorder"},{"name":"Social anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07478796","phase":"PHASE4","title":"TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2025-04-03","conditions":"Depression - Major Depressive Disorder, Depressive Episodes","enrollment":180},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":"Major Depressive Disorder (MDD)","enrollment":30},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT05528224","phase":"NA","title":"Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial","status":"TERMINATED","sponsor":"Shanghai Mental Health Center","startDate":"2022-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":46},{"nctId":"NCT07328373","phase":"","title":"Neurobiological and Genomic Predictors of Relapse in Depression","status":"RECRUITING","sponsor":"Mehmet Kemal Arikan","startDate":"2025-01-01","conditions":"Healthy, Major Depressive Disorder (MDD)","enrollment":204},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT00285935","phase":"NA","title":"Cellular Aging and Neurobiology of Depression Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-12-16","conditions":"Major Depressive Disorder","enrollment":228},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT06746441","phase":"PHASE2","title":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-01","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT06001021","phase":"NA","title":"Cognitive Behavioral Couple Therapy for Perinatal Distress","status":"COMPLETED","sponsor":"Sameera Shafiq","startDate":"2023-08-15","conditions":"Perinatal Depression, Perinatal Anxiety","enrollment":96},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT03222570","phase":"PHASE2","title":"An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2018-02-26","conditions":"Depressive Disorder","enrollment":90},{"nctId":"NCT07025590","phase":"NA","title":"Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-04-22","conditions":"Cardiovascular Diseases (CVD), Depression Anxiety Disorder","enrollment":106},{"nctId":"NCT05002309","phase":"PHASE2","title":"Treatment Interrupts Depression Early","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2021-12-02","conditions":"Depression","enrollment":100},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT06796946","phase":"EARLY_PHASE1","title":"Deprescription of Antidepressants in Primary Care (DAPriCare)","status":"NOT_YET_RECRUITING","sponsor":"University of Huelva","startDate":"2025-04","conditions":"Deprescription, Antidepressants","enrollment":325},{"nctId":"NCT04598230","phase":"PHASE3","title":"Partners in Caring for Anxious Youth","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-02-09","conditions":"Anxiety, Separation, Anxiety, Generalized, Anxiety, Social","enrollment":468},{"nctId":"NCT00667121","phase":"","title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-03-16","conditions":"Breast Cancer, Depression, Hot Flashes","enrollment":88},{"nctId":"NCT02431845","phase":"NA","title":"Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder","status":"RECRUITING","sponsor":"Severance Hospital","startDate":"2013-01-01","conditions":"Obsessive-Compulsive Disorder","enrollment":200},{"nctId":"NCT05588102","phase":"NA","title":"Electronic Training of Elderly Depression With Cognitive Impairment","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2021-05-18","conditions":"Geriatric Depression, Cognitive Impairment","enrollment":128},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT06358014","phase":"NA","title":"Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen","status":"RECRUITING","sponsor":"Xiao Wang","startDate":"2023-05-12","conditions":"Postmenopausal Depression, Estrogen","enrollment":40},{"nctId":"NCT06337539","phase":"","title":"Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants","status":"NOT_YET_RECRUITING","sponsor":"Germans Trias i Pujol Hospital","startDate":"2024-04-01","conditions":"Depression, Inflammation, Antidepressants","enrollment":50},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03993535","phase":"PHASE4","title":"Predicting Treatment Response in Patients With OCD","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2018-10-10","conditions":"Obsessive-Compulsive Disorder","enrollment":250},{"nctId":"NCT05720637","phase":"NA","title":"The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder","status":"COMPLETED","sponsor":"Xiaomei Shao","startDate":"2022-11-01","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT04476030","phase":"PHASE3","title":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-11-09","conditions":"Depressive Disorder, Major","enrollment":440},{"nctId":"NCT04437485","phase":"PHASE2","title":"eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-10-14","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":46},{"nctId":"NCT02458690","phase":"PHASE2","title":"eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-07","conditions":"Depression, Major Depressive Disorder, Dysthymic Disorder","enrollment":216},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05931965","phase":"NA","title":"Combination Therapy of Different Antidepressants With Dietary Supplements","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-05","conditions":"Depression","enrollment":88},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":"Major Depressive Disorder","enrollment":73336},{"nctId":"NCT05850572","phase":"NA","title":"A Study of the Efficacy of Fecal Microbiota Transplantation(FMT) in the Treatment of Depression","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-07","conditions":"Depression","enrollment":100},{"nctId":"NCT03779789","phase":"PHASE4","title":"Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2019-02-01","conditions":"Major Depressive Disorder","enrollment":362},{"nctId":"NCT05832619","phase":"NA","title":"Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder","status":"UNKNOWN","sponsor":"Xiaomei Shao","startDate":"2022-11-01","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT04748276","phase":"","title":"Tracking Response to Antidepressants in Advance of Investigational Trials","status":"UNKNOWN","sponsor":"Adams Clinical","startDate":"2019-01-02","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05730062","phase":"PHASE1","title":"Influence of Oxycodone on Individuals Taking an SSRI","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-03-15","conditions":"Opioid Induced Respiratory Depression, Depressive Disorder, Anxiety Disorders","enrollment":55},{"nctId":"NCT05605002","phase":"NA","title":"Efficacy and Safety of Intradermal Acupuncture for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Xiaomei Shao","startDate":"2022-01-01","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT02022709","phase":"PHASE4","title":"Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2014-01","conditions":"Obsessive-Compulsive Disorder, Anxiety Disorders, Mental Disorders","enrollment":78},{"nctId":"NCT05148169","phase":"PHASE4","title":"A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT03294525","phase":"","title":"Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-01","conditions":"Affective Disorder","enrollment":400},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":"Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders","enrollment":635},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT00564278","phase":"NA","title":"Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-02","conditions":"Depression","enrollment":217},{"nctId":"NCT03068429","phase":"PHASE4","title":"Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-12-01","conditions":"Obsessive-Compulsive Disorder","enrollment":69},{"nctId":"NCT03841474","phase":"NA","title":"The Recovery of Cardiovascular Patients With Depression","status":"UNKNOWN","sponsor":"Klinički Bolnički Centar Zagreb","startDate":"2021-03-01","conditions":"Coronary Artery Disease, Depression, Cardiovascular Diseases","enrollment":150},{"nctId":"NCT02137369","phase":"PHASE4","title":"The ISLAND Study: InSuLa Assessed Needs for Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-09","conditions":"Depression","enrollment":77},{"nctId":"NCT04388202","phase":"PHASE4","title":"Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram","status":"WITHDRAWN","sponsor":"Alto Neuroscience","startDate":"2020-10-15","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT02285699","phase":"NA","title":"The Gut Microbiota in Obsessive-Compulsive Disorder","status":"COMPLETED","sponsor":"McMaster University","startDate":"2014-11-01","conditions":"Obsessive-Compulsive Disorder","enrollment":43},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT04430556","phase":"NA","title":"Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2018-07-01","conditions":"Major Depressive Disorder, Anxiety Disorders","enrollment":30},{"nctId":"NCT00742573","phase":"PHASE2","title":"Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2008-08","conditions":"Major Depressive Disorder","enrollment":170},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT00234312","phase":"PHASE4","title":"Medications for the Treatment of Dysthymic Disorder and Double Depression","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2005-09","conditions":"Depression, Dysthymia","enrollment":40},{"nctId":"NCT00386243","phase":"NA","title":"Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2007-12","conditions":"Low Back Pain, Pain, Pain, Intractable","enrollment":242},{"nctId":"NCT02269540","phase":"EARLY_PHASE1","title":"A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2014-10","conditions":"Major Depressive Disorder","enrollment":10},{"nctId":"NCT00854100","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2009-06-30","conditions":"Major Depressive Disorder","enrollment":231},{"nctId":"NCT00787501","phase":"PHASE1","title":"Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2008-06","conditions":"Major Depressive Disorder","enrollment":98},{"nctId":"NCT03558256","phase":"NA","title":"The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2016-05-16","conditions":"Major Depressive Disorder","enrollment":105},{"nctId":"NCT01903447","phase":"PHASE4","title":"Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2013-12-13","conditions":"Internalizing Psychopathologies (IPs) Depression and Anxiety","enrollment":271},{"nctId":"NCT01360866","phase":"PHASE3","title":"Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2944},{"nctId":"NCT02469545","phase":"PHASE2","title":"Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment","status":"COMPLETED","sponsor":"Medical University of Bialystok","startDate":"2014-06","conditions":"Depression, Anxiety Disorder","enrollment":60},{"nctId":"NCT02441387","phase":"","title":"Predictors of the Outcome of Late Life Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT01469377","phase":"PHASE2","title":"Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12-15","conditions":"Major Depressive Disorder","enrollment":819},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02178696","phase":"PHASE4","title":"Predictors of Antidepressant Response","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-01","conditions":"Depression","enrollment":44},{"nctId":"NCT01916824","phase":"PHASE4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Major Depressive Disorder, Healthy Controls","enrollment":53},{"nctId":"NCT00564564","phase":"PHASE4","title":"Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2006-01","conditions":"Obsessive Compulsive Disorder","enrollment":21},{"nctId":"NCT01032018","phase":"PHASE1, PHASE2","title":"Comparison of Depression Interventions After Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Columbia University","startDate":"2010-01","conditions":"Acute Coronary Syndrome, Depression","enrollment":150},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT00118430","phase":"PHASE4","title":"Stepped Care for Depression and Musculoskeletal Pain","status":"COMPLETED","sponsor":"Indiana University","startDate":"2004-09","conditions":"Pain, Depression","enrollment":500},{"nctId":"NCT01944657","phase":"NA","title":"Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study","status":"WITHDRAWN","sponsor":"Sheppard Pratt Health System","startDate":"2013-09","conditions":"1. Major Depressive Disorder","enrollment":""},{"nctId":"NCT00955474","phase":"PHASE4","title":"Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder With Psychotic Features","enrollment":32},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT00767624","phase":"PHASE2, PHASE3","title":"TRIAD - Treatment of Insomnia and Depression","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-12","conditions":"Sleep Initiation and Maintenance Disorders, Depression","enrollment":150},{"nctId":"NCT02873234","phase":"","title":"A Study of Chinese Medicine Treating Depression","status":"UNKNOWN","sponsor":"The Third Affiliated Hospital of Beijing University of Chinese Medicine","startDate":"2016-06","conditions":"Depression","enrollment":4600},{"nctId":"NCT02023567","phase":"NA","title":"Objective Diagnostic Markers and Personalized Intervention in MDD Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2013-11","conditions":"Depressive Disorder, Major","enrollment":2400},{"nctId":"NCT02320240","phase":"","title":"Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2013-06","conditions":"Depression, Acute Kidney Injury","enrollment":3255526},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT01796132","phase":"PHASE4","title":"Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2012-08","conditions":"Depressive Disorder, Lactation","enrollment":500},{"nctId":"NCT00129467","phase":"NA","title":"Methylphenidate for Depressed Cancer Patients Receiving Palliative Care","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-02","conditions":"Depression, Palliative Care, Cancer","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"escitalopram and sertraline","genericName":"escitalopram and sertraline","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Both escitalopram and sertraline are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain by blocking its reabsorption at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}